ORIGINAL RESEARCH article

Front. Immunol.

Sec. Vaccines and Molecular Therapeutics

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1561572

This article is part of the Research TopicData-Driven Vaccine Design for Microbial-Associated DiseasesView all 8 articles

Integrating Bioinformatics to Explore HPV-31 and HPV-52 E6/E7 Proteins: From Structural Analysis to Antigenic Epitope Prediction

Provisionally accepted
  • 1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China
  • 2Department of Gastrointestinal Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China
  • 3The First Clinical College, China Medical University, Shenyang , Liaoning,, China

The final, formatted version of the article will be published soon.

Cervical cancer is the most common malignant neoplasm of the female reproductive tract. Infection with human papillomavirus (HPV) has been strongly associated with cervical cancer. Previous bioinformatics studies have examined the E6 and E7 proteins of high-risk HPV types; however, subtype-specific analyses for HPV-31 and HPV-52 remain limited. Understanding the structure and properties of the E6 and E7 proteins of HPV-31 and HPV-52 is crucial to elucidating their functions and advancing vaccine development. A bioinformatics approach was employed to predict the physicochemical properties, hydrophilicity, protein structure, glycosylation sites, phosphorylation sites, terminal positions, signal peptide cleavage sites, transmembrane regions, homology, and dominant epitopes of the E6 and E7 proteins of HPV-31 and HPV-52. For HPV-31 E6, an instability index (II) of 43.93 indicated that the protein is unstable; potential B-cell epitopes were identified at residues 55–61 (RDDTPYG), 112–116 (PEEKQ), and 125–131 (FHNIGGR), while T-cell epitopes were predicted at residues 45–53 (FAFTDLTIV) and 72–80 (KVSEFRWYR). HPV-52 E6 exhibited an instability index (II) of 55.57, with B-cell epitopes at residues 110–119 (LCPEEKERHV) and 129–141 (MGRWTGRCSECWR), and T-cell epitopes at residues 45–53 (FLFTDLRIV) and 82–87 (SLYGKT). HPV-31 E7, with an instability index (II) of 51.05, exhibited B-cell epitopes at residues 8–17 (QDYYLDLQP), 16–20 (QPEAT), 29–41 (PDSSDEEDVIDEP), and 42–48 (AGQAKPDT), and T-cell epitopes at residues 7–15 (TLQDYVLDL) and 82–90 (LLMGSFGIV). HPV-52 E7, with an instability index (II) of 49.15, exhibited B-cell epitopes at residues 11–19 (YILDLQPET), 23–27 (HCYEQ), 29–38 (GDSSDEEDTD), and 36–48 (DTDGVDRPDGQAE), and T-cell epitopes at residues 53–59 (NYYIVTY) and 84–90 (MLLGTLQ). In summary, the E6 and E7 proteins of HPV-31 and HPV-52 contain dominant epitopes for both T cells and B cells. These findings delineate subtype-specific immunogenic regions and establish a foundation for experimental validation and vaccine design.

Keywords: E6 / E7, Human papillomavirus 31, Human papillomavirus 52, bioanalysis, Antigen epitope

Received: 16 Jan 2025; Accepted: 16 Jun 2025.

Copyright: © 2025 Cai, Feng, Dong and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yanling Meng, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110000, Liaoning Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.